Human milk and mucosa-associated disaccharides impact on cultured infant fecal microbiota.

Scientific Reports
Antonio Rubio-Del-CampoMaría J Yebra

Abstract

Human milk oligosaccharides (HMOs) are a mixture of structurally diverse carbohydrates that contribute to shape a healthy gut microbiota composition. The great diversity of the HMOs structures does not allow the attribution of specific prebiotic characteristics to single milk oligosaccharides. We analyze here the utilization of four disaccharides, lacto-N-biose (LNB), galacto-N-biose (GNB), fucosyl-α1,3-GlcNAc (3FN) and fucosyl-α1,6-GlcNAc (6FN), that form part of HMOs and glycoprotein structures, by the infant fecal microbiota. LNB significantly increased the total levels of bifidobacteria and the species Bifidobacterium breve and Bifidobacterium bifidum. The Lactobacillus genus levels were increased by 3FN fermentation and B. breve by GNB and 3FN. There was a significant reduction of Blautia coccoides group with LNB and 3FN. In addition, 6FN significantly reduced the levels of Enterobacteriaceae family members. Significantly higher concentrations of lactate, formate and acetate were produced in cultures containing either LNB or GNB in comparison with control cultures. Additionally, after fermentation of the oligosaccharides by the fecal microbiota, several Bifidobacterium strains were isolated and identified. The results pres...Continue Reading

References

Oct 1, 1992·Journal of Pediatric Gastroenterology and Nutrition·K OgawaL Bustos Fernández
Jan 1, 1991·Journal of Bacteriology·W G WeisburgD J Lane
Mar 1, 1994·Scandinavian Journal of Gastroenterology·H HoveP B Mortensen
Dec 14, 2002·FEMS Microbiology Letters·Susan E PrydeHarry J Flint
Jul 9, 2004·Applied and Environmental Microbiology·Miguel GueimondeSeppo Salminen
Jul 14, 2005·Annual Review of Nutrition·David S NewburgArdythe L Morrow
Apr 6, 2006·Glycobiology·Simon ParryAnn Harris
Jan 27, 2007·Journal of Pediatric Gastroenterology and Nutrition·Chongxin WangYuichiro Yamashiro
Mar 27, 2007·Journal of Applied Microbiology·M GueimondeS Salminen
Sep 11, 2007·Research in Microbiology·Luz Adriana Sarmiento-RubianoMaría Jesús Yebra
Jan 10, 2008·Applied Microbiology and Biotechnology·Masahiro NakajimaMotomitsu Kitaoka
Aug 4, 2010·Proceedings of the National Academy of Sciences of the United States of America·Angela M ZivkovicDavid A Mills
Aug 7, 2010·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Akira Kobata
Nov 26, 2010·Applied and Environmental Microbiology·Jesús Rodríguez-DíazMaría J Yebra
Dec 15, 2010·Bioscience, Biotechnology, and Biochemistry·Shinya Fushinobu
Mar 23, 2011·Applied and Environmental Microbiology·Fausta SerafiniMarco Ventura
Apr 13, 2011·Genes & Nutrition·Karina PokusaevaDouwe van Sinderen
Apr 20, 2011·Early Human Development·Patricia Peso EcharriMiguel Gueimonde
Jan 17, 2012·BMC Bioinformatics·Ana Brânduşa Pavel, Cristian Ioan Vasile
Mar 28, 2012·The Journal of Biological Chemistry·Haruko SakuramaTakane Katayama
Apr 4, 2012·Journal of AOAC International·George T Macfarlane, Sandra Macfarlane
May 1, 2012·Applied and Environmental Microbiology·Jesús Rodríguez-DíazMaría J Yebra
May 19, 2012·PloS One·Francesca TurroniMarco Ventura
Feb 6, 2013·Journal of Agricultural and Food Chemistry·Brittany M Vester BolerGeorge C Fahey
Mar 9, 2013·Bioscience, Biotechnology, and Biochemistry·Tadasu UrashimaSadaki Asakuma

❮ Previous
Next ❯

Citations

May 4, 2021·Gut Microbes·Antonio Rubio-Del-CampoMaría J Yebra

❮ Previous
Next ❯

Datasets Mentioned

BETA
MN650609
MN650619

Methods Mentioned

BETA
transglycosylation
electrophoresis
PCR

Software Mentioned

BLAST
GraphPad Prism
PyElph
GraphPad

Related Concepts

Related Feeds

Bacteriotherapy (ASM)

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.

Bacteriotherapy

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.